Regulation of Boundary Products in Taiwan

Shirley Pan

Section of Generic Drugs Division of Medicinal Products




Taiwan Profile

- Population: 23.4 million
- Area: about 36,000 sq.km.
 (14,400 sq. m.)
- Capital: Taipei City
- 99.8% citizen covered by NHI
 - A single payer national health insurance system
- Pharmaceutical market:
 - US\$ 5.6 billion in 2016
 - Aging population






Nonprescription Products are Tools




Ministry of Health and Welfare (MOHW) Organization Chart






Life Cycle Management of Medicinal Products




Classification and Retail Distribution




衛生福利部 食品藥物管理署 FDA Food and Drug Administration

Distribution Chart of Drug Licenses






Regulatory Framework





Classification of Capsule and Tablet Products

- Considerations
- ✓ Ingredients and Contents
- ✓ Dosage and Usage
- ✓ Intended use





Determination Criteria for Vitamins in Tablet or Capsule Form

items	Standard for specification, Scope, Application and Limitation of Food additives Upper limit in daily dosage	Dietary Reference Intake 150%
Vit. A	10000 I.U. (3000 µ g)	1050 µ g
Vit. B ₁	50 mg	1.95 mg
Vit. B ₂	100 mg	2.25 mg
Vit. B ₆	80 mg	2.1 mg
Vit. B ₁₂	1000 µ g	3.6 µ g
Vit. C	1000 mg	150 mg
Vit. D	800 I.U. (20 µ g)	15 µ g
Vit. E	400 I.U. (268 mg)	18 mg
Vit. K	500 µ g	140 µ g
Nicotinic Acid	100 mg	25.5 mg
Folate	800 µ g	600 µ g



Milestones

1970 1980 1990 2000 2010 2015~

Pharmaceutical Affair Act 1970

Pharmaceutical Affair Act Enforcement Rules 1973


Regulations for Registration of Medicinal Products₁₉₇₅

OTC program working group 1995

OTC monograph 1996

OTC Expert advisory committee 1999









OTC Monographs

- For drugs commonly used to alleviate mild symptoms, monographs with active ingredients and dosage range were developed.
- Manufacturers can design formulas within the scope of the monograph, and not be subject to the limitations of the reference drugs.
- It's easy to follow standard usage, precautions, warnings and labeling, to provide people with convenience and safety.





OTC Medicines Registration



Dossier Requirement

Evaluation	NDA	Generics	OTC Monograph Drug Application	
Reference Drug	Not required	Required	Compiled with Monograph	
Safety Efficacy	Pharm/ToxPK/PD/BA/BEClinical trials	Bioequivalence (BE) as a surrogate to clinical trial	BE may be required in some cases	
Quality	 Chemistry, Manufacturing and Controls(CMC) PIC/S GMP GLP, GCP, 			
Labeling	Labeling (direction of use)			



Labeling Revision

[Ingredients]

Active Ingredients and contents Inactive ingredients (excipients)

【 Uses (indications) 】

[Precautions]

- ✓ Do not use if...
- ✓ Seek for doctor diagnosis and treatment before use if...
- ✓ Consult a doctor/pharmacist before use if...
- ✓ Other precautions

[Directions]

[Warnings]

- ✓ Stop using and consult a doctor or pharmacist with this instruction if the following symptoms occur (shown in tables)
- ✓ Stops using and receive doctor diagnosis and treatment if the following symptoms occur

[Package]

Consumer Language

Begin with the <u>Must-Know</u> Before-Use information

Follow with the *Direction*

Follow with What-to-Do when uncomfortable symptoms occur after taking the medicine






~QR Code

Easy to read by using a smart phone scanning

> Name of the product, use (indications), usage & dosage, dosage form and shape, consultation phone





用法用量:成人及十二歲(含)以上兒童:每日一顆 ZIMYNTYNE錠劑。十二歲以下不宜自行使用。

衛生福利部食品藥物管理署 台北市南港區昆陽往





Regulations for Different Categories

	Prescription Drugs	Pharmacy Drugs	General Sale Drugs		
License required					
Pre-approval	V	V	V		
Distribution					
Hospital/Clinical	V	V	V		
Pharmacy	V	V	V		
General distribution	X	Х	V		
Internet	X	Х	V		
Advertisement					
Pre-approval	V	V	V		
Mass media	Х	V	V		

Perspectives

1. provide high Healthcare quality service **Provider** to the public 2. encourage Health the responsible **Authority** self-care & selfmedication 1. recognize the positive role in selfmedication Industry 2. encourage 1. develop and competition invest in selfbetween medication companies products 2. support public health objectives



The 4th Self-CARER Annual Meeting

Date: March 20 – 22, 2018

Venue: National Taiwan University Hospital (NTUH) International

Convention Center, Taipei (to be confirmed)

Contact Information

Ms Wei Lin Chien,

TFDA

katsura-

Email: weilin@fda.gov.tw yoshihiro@pmda.go.jp drsuchart@gmail.com

Yoshihiro Katsura, PMDA Suchart Chongprasert,

Thai FDA



Thank You for Your Attention!



For more information, please visit http://www.fda.gov.tw





















